Researchers have developed a melanin-enhanced cancer immunotherapy technique that can also serve as a vaccine, based on early experiments done in a mouse model. The technique is applied via a transdermal patch.
In a first-of-its-kind study, University of California San Diego School of Medicine researchers report that a blood sample, or liquid biopsy, can reveal which patients will respond to checkpoint inhibitor-based immunotherapies.
Immunotherapy — often in the form of allergy shots — can combat the runny nose, itchy eyes, congestion, sneezing and sinus pressure of persistent hay fever. But it can't be done in less than three years, British researchers report.
Treating one of the most common and deadly forms of skin cancer with a combination of immunotherapy options may improve survival and lower the risk of life-threatening events in the patients diagnosed in the late stages, a new study has found.
Lung cancer patients who also have autoimmune diseases are not eligible for the latest immunotherapy treatments, according to a team of researchers from the University of Texas Southwestern Medical Center.
In a study, an international collaboration of investigators from Dana-Farber, Harvard Medical School, Boston Children's Hospital, and the University of Strasbourg uncovered a mechanism that allows key immune system cells to keep a steady rein on their more belligerent brother cells, thereby protecting normal, healthy tissue from assault. The discovery has powerful implications for cancer immunotherapy researchers say: By blocking the mechanism with a drug, it may be possible to turn the attack-suppressing cells into tumor-attacking cells.
A drug with the potential to reverse resistance to immunotherapy has been developed by scientists at the University of Southampton. It has shown great promise in pre-clinical models and will be available to patients with certain leukemias and non-Hodgkin lymphomas in clinical trials later this year.